23rd week of 2010 patent applcation highlights part 39 |
Patent application number | Title | Published |
20100144690 | MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION - Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm | 2010-06-10 |
20100144731 | Novel Biccyclic Compounds As GATA Modulators - Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. | 2010-06-10 |
20100144732 | PYRIMIDINE KINASE INHIBITORS - The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein Q, X, Y, Z, R | 2010-06-10 |
20100144733 | Compounds, compositions and methods comprising heteroaromatic derivatives - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 2010-06-10 |
20100144734 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists - The present invention relates to 1,2,3-triazole derivatives which can be used as cannabinoid CB1 receptor antagonists. In addition, the compound of the 1,2,3-triazole derivatives in the present invention can be formulated into a pharmaceutical composition for treating indications relative to signal transduction of CB1 receptors. | 2010-06-10 |
20100144735 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY - The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenyloxazolidinone derivatives, processes for making compounds as well as antimicrobial compositions containing said derivatives as active ingredients and methods of treating bacterial infections with the said derivatives. | 2010-06-10 |
20100144736 | NOVEL BIPHENYL THIO-UREA DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - The invention relates to novel biphenyl thio-urea derivatives of Formula (I), wherein A represents hydroxy or tetrazolyl; R | 2010-06-10 |
20100144737 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION - The present invention relates to methods and compounds useful for inhibiting T helper cell differentiation. Methods and compounds for decreasing IL-12 signaling in T helper cells are also provided. | 2010-06-10 |
20100144738 | INHIBITORS OF C-MET AND USES THEREOF - The present invention relates to compounds and methods use as inhibitors of c-Met. Certain compounds of the subject invention have the following structural formula (I). Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention. | 2010-06-10 |
20100144739 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF - The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders. | 2010-06-10 |
20100144740 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS - A synergistic combination of a vanilloid receptor VR-1 antagonist and an NSAID or a pharmaceutically acceptable salt or solvate of either or both compounds thereof. | 2010-06-10 |
20100144741 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS - The invention relates to novel cyclic compounds of the formula (I), in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them. | 2010-06-10 |
20100144742 | MULTIPLY-SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS - The invention relates to multiply-substituted tetrahydronaphthalene derivatives of formula (I) | 2010-06-10 |
20100144743 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES - Compositions for inhibiting the catalytic activity of tyrosine kinases comprising compounds represented by Formulas (I), (II), and (III). Methods for treating proliferative diseases comprising administering a therapeutically effective amount of the above compositions. | 2010-06-10 |
20100144744 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS - Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d). | 2010-06-10 |
20100144745 | Pyrrolopyrazinyl Urea Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, | 2010-06-10 |
20100144746 | METHOD FOR RESTRUCTURING A BIOLOGICAL TISSUE COMPRISING COLLAGEN FIBRILS AND RELATIVE USES - A method for restructuring a biological tissue comprising collagen fibrils selected from a venous tissue, a cardiac valvular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia or a tissue of a muscular aponeurosis, comprising the following operational steps: a) bringing into contact a biological tissue comprising collagen fibrils with a cross-linking chemical composition able to induce cross-linking of collagen fibrils consequent to activation through electromagnetic radiation; b) activating said cross linking chemical composition through exposure to an electromagnetic radiation; c) cross-linking the collagen fibrils of said biological tissue in order to obtain a restructured biological tissue. The method according to the invention can be applied to recover a venous continence and both a venous and a cardiac valve diameter. The method reduces the visibility of cutaneous wrinkles, reinforces or repairs tendons, muscular fascia and aponeurosis as well as to heals surgical or traumatic cutaneous wounds or cutaneous ulcers. | 2010-06-10 |
20100144747 | 1H-QUINAZ0LINE-2,4-DIONES - The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) | 2010-06-10 |
20100144748 | METHODS INVOLVING ALDOSE REDUCTASE INHIBITORS - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma. | 2010-06-10 |
20100144749 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS - The present invention provides compositions and methods for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib. | 2010-06-10 |
20100144750 | Use of N-Phenyl-2-Pyrimidineamine Derivatives Against Mast Cell-Based Diseases Like Allergic Disorders - Use of the N-phenyl-2-pyrimidine-amine derivatives of formula I, | 2010-06-10 |
20100144751 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS - Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1. | 2010-06-10 |
20100144752 | Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes - The invention relates to heterocyclylamide-substituted thiazoles, pyrroles and thiophenes and to processes for preparing them, to their use for the treatment and/or prophylaxis of diseases, and to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, particularly for use as antiviral agents, especially against cytomegaloviruses. | 2010-06-10 |
20100144753 | CRYSTAL MODIFICATIONS OF TRANSMISSION DYES - Disclosed is the use of an aqueous dispersion comprising (a) a micronized sparingly soluble organic benzophenone derivative of formula (1), selected from the crystal modifications (B) and (C), wherein the crystal modification (B) is characterized by a peak in the X-ray diffraction pattern at a d-spacing of about 7.70; and wherein the crystal modification (C) is characterized by a peak in the X-ray diffraction pattern at a d-spacing of about 7.06; and (b) a dispersing agent selected from anionic, non-ionic and amphoteric surfactants; for protecting the human skin from browning and skin aging. The new crystal modification (C) represents a thermodynamically stable compound of formula (1) at 25° C. This modification is therefore suitable in dispersions comprising micro-fine particles. | 2010-06-10 |
20100144755 | Novel Compounds - Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use use in therapy as CSBP/RK/p38 kinase inhibitors. | 2010-06-10 |
20100144756 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (I), wherein X | 2010-06-10 |
20100144757 | DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHYRIDONES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to 7-alkynyl-1,8-naphthyridones of formula (I): | 2010-06-10 |
20100144758 | AZAINDOLE P2X3 AND P2X2/3 MODULATORS - The application discloses compounds of the Formula I: | 2010-06-10 |
20100144759 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 - The invention provides N-(fluoro-pyrazinyl)-phenylsulfonamides of formula (I) | 2010-06-10 |
20100144760 | NOVEL COMPOUNDS - Disclosed are N-{[(1R,4S,6R)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals. | 2010-06-10 |
20100144781 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GENE - The present application is directed to the use of genetic polymorphism in the ErbB4 gene to predict whether a patient is likely to respond to psychotic medication Paliperidone. The polymorphism in the ErbB4 gene is also used to predict whether a patient is likely to display placebo effect among patients in need of psychotic treatment. A method of treating patients with antipsychotic medication Paliperidone using the polymorphism in the ErbB4 gene and a kit of are also provided. | 2010-06-10 |
20100144782 | DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHYRIDONES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to compounds of formula (I): | 2010-06-10 |
20100144783 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE - Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. | 2010-06-10 |
20100144785 | FUNGICIDE N-6-MEMBERED FUSED (HETERO) ARYL-METHYLENE-N-CYCLOALKYL CARBOXAMIDE DERIVATIVES - The present invention relates N-(aromatic, 6-membered, fused, (hetero)aryl-methylene)-N-cycloalkyl carboxamide derivatives, their thiocarboxamide or N-substituted carboximidamide analogues, all of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents O, S, N—R | 2010-06-10 |
20100144786 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS - Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component. | 2010-06-10 |
20100144787 | Quinolines and Their Therapeutic Use - Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R | 2010-06-10 |
20100144788 | 4- [2- (4-METHYLPHENYLSULFANYD-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION - The use of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and acid additions salts thereof for the treatment of ADHD, melancholia, treatment resistant depression or residual symptoms in depression is provided. | 2010-06-10 |
20100144789 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity - This invention provides a compound of formula (I): wherein R | 2010-06-10 |
20100144790 | Use of Thalidomide for Alzheimers Disease Treatment and Prevention - β-secretase (BACE) is a biomarker for MCI and Alzheimer's disease. BACE1 protein level and the enzymatic activity level increase in the brain, and in the CSF in AD and MCI patients. Increased BACE1 levels in CSF are related to neuronal death and synaptic damages, which contribute to AD-related cognitive deficits. BACE1 inhibitors may be used as therapeutic compounds for clinical use for the disease treatment and prevention. Use of Thalidomide, an effective BACE1 inhibitor, reduces the BACE1 enzymetic activity and protein levels, and the Aβ production that marks the neurodegenerative progression associated with AD. | 2010-06-10 |
20100144801 | MUSCARINIC RECEPTOR ANTAGONISTS - The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims. | 2010-06-10 |
20100144802 | Small Molecule Inhibitors for Immune Modulation - Methods of treating immunosuppression by administering a therapeutic amount of a tryphostin compound of the formula: | 2010-06-10 |
20100144803 | INSECTICIDAL N-SUBSTITUTED (6-HALOOALKYLPYRIDIN-3-YL)-ALKYL SULFOXIMINES - N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects. | 2010-06-10 |
20100144804 | Polymorph of a Pharmaceutical - A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed. | 2010-06-10 |
20100144805 | Regulation of protein synthesis - A composition and method for inhibiting proliferation of a tumor cell compared to a non-tumor cell. Also described are methods of screening for a composition that inhibits cap-dependent translation compared to cap-independent translation of proteins. | 2010-06-10 |
20100144806 | Cyclopropanecarboxylic Acid Compound - A compound of the formula (I): | 2010-06-10 |
20100144807 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 5 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed. | 2010-06-10 |
20100144808 | SUBSTITUTED ISOXAZOLINE OR ENONE OXIME COMPOUND, AND PEST CONTROL AGENT - Disclosed is a novel pest control agent, in particular a pesticide or a miticide. Specifically disclosed are a substituted isoxazoline compound or a substituted enone oxime compound represented by the general formula (1) below or the general formula (2) below, and a pest control agent containing any of them. (In the formulae, the symbols are as defined in the description.) | 2010-06-10 |
20100144809 | NOVEL BENZAMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel benzamidine derivatives of formula (I) that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels. A stereoisomer or a mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically-acceptable addition salt thereof, wherein B may be absent (i.e. no heterocyclic ring is formed); and when absent, the nitrogen next to B holds a hydrogen (i.e. “NH”), and A represents NH | 2010-06-10 |
20100144810 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 2010-06-10 |
20100144821 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS - The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, Aβ protein or α-synuclein protein aggregation. | 2010-06-10 |
20100144822 | Use of Inhibitors of the Degradation of P27, in Particular Argyrin and Derivatives Thereof, for the Treatment of Proliferative Diseases - The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular Argyrin and derivatives thereof, preferably Argyrin A, for the treatment of proliferative diseases, such as cancer, as well as the derivatization of said macrocycles. | 2010-06-10 |
20100144823 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. | 2010-06-10 |
20100144824 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 2010-06-10 |
20100144825 | Renin Inhibitors - The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. | 2010-06-10 |
20100144826 | Salinosporamides and Methods for Use Thereof - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet | 2010-06-10 |
20100144827 | NOVEL CONJUGATES OF POLYUNSATURATED FATTY ACIDS WITH AMINES AND THERAPEUTIC USES THEREOF - The present application discloses conjugates comprising an aminic moiety covalently linked to a hydrophobic moiety, through an amidic bond, which are selective inhibitors of COX-2 enzyme and can be beneficially used in the treatment of various inflammatory disease or disorder and cancer. | 2010-06-10 |
20100144828 | CAFFEOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USAGE THEREOF - The present invention provides caffeoylquinic acid derivatives and a method of preparing for the same, and also provides pharmaceutical compositions containing caffeoylquinic acid derivatives, and uses of caffeoylquinic acid derivatives in preparation of a medicament for the treatment or prophylaxis of virus diseases, in particular, uses of respiratory syncytial virus and hepatitis B virus, which has the characteristics of safety, high effectiveness and low toxicity. | 2010-06-10 |
20100144829 | Novel Receptor Antagonists and Their Methods of Use - The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor | 2010-06-10 |
20100144830 | CANCER CELL IDENTIFICATION MARKER AND CANCER CELL PROLIFERATION INHIBITOR - Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1γ (HP1γ), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1γ gene, such as siRNAs to human HP1γ. | 2010-06-10 |
20100144841 | CONTROL OF NK CELL FUNCTION AND SURVIVAL BY MODULATION OF SHIP ACTIVITY - Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP | 2010-06-10 |
20100144842 | RNA Interference Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) - This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220, NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2 | 2010-06-10 |
20100144843 | RNAI THERAPEUTIC FOR RESPIRATORY VIRUS INFECTION - Double stranded siRNA molecules for combatting a respiratory virus, wherein the strands of an siRNA molecule may be from about 15 to about 60 nucleotides, and uses thereof. One strand of an siRNA molecule can be a nucleic acid sequence identical to a conserved site, or a variant thereof, within the nucleic acid sequence of the respiratory virus. | 2010-06-10 |
20100144844 | RNAi-MEDIATED INHIBITION OF H1F1A FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions. | 2010-06-10 |
20100144845 | OLIGONUCLEOTIDE SYSTEMS FOR TARGETED INTRACELLULAR DELIVERY - The present invention provides methods for deriving oligonucleotides for specific internal delivery to one or more target cell types (e.g., cancer cells). The method generally includes selecting at least once with a target cell type to provide a plurality of internalizing oligonucleotides for the target cell type, and in some embodiments, counter-selecting at least once with a non-target cell type to provide a plurality of oligonucleotides that do not bind to features present in the non-target cell type. Therapeutic and diagnostic compositions including the oligonucleotides, and methods of treatment are also provided. | 2010-06-10 |
20100144846 | Oligoribonucleotides and uses thereof - The invention relates to immunostimulatory RNA oligonucleotides (ORN). In particular the ORN have an immunostimulatory ORN motif directly or indirectly flanked by a 3′ poly G motif and optionally a 5′ poly-G motif. The invention also relates to methods including therapeutic methods and screening methods and related kits for use of the ORN. | 2010-06-10 |
20100144847 | FUSION POLYPEPTIDE SUITABLE AS A CYTOTOXIN - The present invention relates to fusion polypeptides including (a) a binding site for a cytoskeleton component and (b | 2010-06-10 |
20100144848 | DNA CONTROLLED ASSEMBLY OF LIPID MEMBRANES - The present invention relates to detection of target nucleic acids by target nucleic acid induced liposome assembly. The invention provides oligonucleotides for use in detection and a method of detecting target nucleic acids. Other aspects of the invention are use of the oligonucleotide of the invention for detection, a kit for detection, a method of treatment comprising administrating the oligonucleotide of the invention and a pharmaceutical composition comprising the oligonucleotide of the invention. | 2010-06-10 |
20100144849 | METHOD FOR INHIBITING SIGNALING MEDIATED BY ErbB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF - An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug. | 2010-06-10 |
20100144850 | Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis - There is provided herein methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer, along with methods of identifying anti-pancreatic cancer agents. | 2010-06-10 |
20100144851 | RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (siNA) - This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor (ECGF1 and/or ECGF1r) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of ECGF1 and/or ECGF1r genes. | 2010-06-10 |
20100144852 | Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses - Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R | 2010-06-10 |
20100144853 | NOVEL COMBINED ADMINISTRATION - The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder. | 2010-06-10 |
20100144854 | USE OF RHODAMINE 6G AS A MEDICINAL AGENT FOR TREATING MALIGNANT NEOPLASMS AND AMILOIDOSES - Rhodamine 6G is used as a medical agent for treating malignant neoplasms and amyloidoses at a dosage ranging from 1 mg to 10 g in the form of an aqueous, physiological, or alcoholic solution. For different purposes, the rhodamine G6 solution is orally administered before or after meals, or rhodamine G6 solution is rectally administered or the rhodamine G6 1% solution is intravenously injected, or the rhodamine G6 is administered in the form if a suppository or a 1-5% ointment. | 2010-06-10 |
20100144855 | APPLICATION OF SEDOISOPROSAN FOR PREPARATION OF MEDICINE FOR TREATMENT OF HUMAN HBeAg POSITIVE CHRONIC HEPATITIS B - The present invention disclosed the application of sedoisoprosan for preparation of medicine for therapy on human HBeAg positive chronic hepatitis B. Results of the clinical trials indicated that sedoisoprosan could effectively inhibit hepatitis B virus, the anti-virus effect is enhanced as the dose is increased and the incidence of adverse events is low. Thus, sedoisoprosan is safe and effective for therapy on human HBeAg positive chronic hepatitis B. | 2010-06-10 |
20100144856 | PRENYLFAVANONE COMPOUNDS AND USES THEREOF - The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds. | 2010-06-10 |
20100144857 | PRENYLFLAVANONE COMPOUNDS AND USES THEREOF - The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds. | 2010-06-10 |
20100144858 | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator - An mGluR4 receptor positive allosteric modulator is useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders such as Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonian, Gilles de la Tourette syndrome, Huntington's disease, tremor, chorea, myoclonus, tick disorder, and dystonia. | 2010-06-10 |
20100144859 | DIMERIC AVERMECTIN AND MILBEMYCIN DERIVATIVES - This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections and infestations in animals or for combating pests in plants or plant propagation material. | 2010-06-10 |
20100144860 | Transglutaminase Inhibitor Comprising EGCG And A Method For Producing Thereof - The present invention relates to a transglutaminase inhibitor comprising epigallocatechin gallate (hereinafter, referred to as EGCG). More particularly, the present invention relates to a transglutaminase inhibitor comprising EGCG which effectively inhibits the activity of transglutaminase, the overexpression of which is responsible for the etiology of various diseases, and to novel uses thereof. According to the present invention, provided is a transglutaminase inhibitor and a method of inhibiting transglutaminase, featuring the use of EGCG as an active ingredient. Featuring the use of EGCG, the novel method of inhibiting transglutaminase according to the present invention is safely applied to patients who suffer from the diseases caused by the overexpression of transglutaminase, thereby obtaining an inhibitory effect against transglutaminase without casuing side-effects. | 2010-06-10 |
20100144871 | Treating muscle wasting with selective androgen receptor modulators - This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and/or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof. | 2010-06-10 |
20100144872 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation - There is provided compounds of formula (I), wherein R | 2010-06-10 |
20100144873 | TREATMENT OF MYOCARDITIS USING FTS - Disclosed are methods of treating myocarditis by—administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. | 2010-06-10 |
20100144874 | Use of a PPARalpha Agonist and Metformin for Decreasing the Serum Triglycerides - The present invention relates to the combined use of a PPARα agonist and metformin for decreasing serum triglycerides. | 2010-06-10 |
20100144875 | Compositions and Methods for Preserving Brain Function - Compositions and methods for preventing, reducing, or delaying decline in one or more of cognitive function, motor function, cerebrovascular function, or behavior in animals, particularly geriatric animals, are disclosed. The compositions and methods utilize medium chain triglycerides. | 2010-06-10 |
20100144876 | MODULATOR - The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR | 2010-06-10 |
20100144877 | Synergistic Enhancement of Calcium Propionate - A novel composition comprised of a monocarboxylic fatty acid synergistically enhanced with a dual quaternary ammonium compound to provide immediate fungal and sporicidal destruction with long term residual resistance. | 2010-06-10 |
20100144878 | Nutritional supplement or functional food comprising oil combination - The present invention relates to a nutritional supplement or functional food comprising or consisting of (a) a nut oil in an amount of 0.5 to 20 percent by volume; (b) one or more ω-3-fatty acid sources in an amount of 10 to 50 or 10 to 90 percent by volume, the total amount of ω-3-fatty acids in each of the ω-3-fatty acid sources being at least 20 percent by volume; and (c) a flavour carrier in an amount of 10 to 89.5 percent by volume. Additionally the present invention relates to salad dressing consisting of or comprising the nutritional supplement or functional food of the invention. Finally the present invention relates to the use of the nutritional supplement or functional food of the invention as salad dressing. | 2010-06-10 |
20100144879 | Antibiotic Compound - Fermentation of a nutrient medium with a eubacterium | 2010-06-10 |
20100144880 | AMINO ACID INHIBITORS OF PLASMIN - The present invention relates to new amino acid inhibitors of plasmin, pharmaceutical compositions thereof, and methods of use thereof | 2010-06-10 |
20100144891 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to methods for modulating, disrupting or enhancing the clearance of copper/zinc superoxide dismutase 1 (SOD1) aggregates in astrocytes or motor neurons in a subject, by administering a medicament comprising a therapeutically effective amount of a cyclohexanehexyl derivative. In another aspect, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula III or IV useful in preventing or treating amyothropic lateral sclerosis (ALS), improving motor neuron function and slowing the degeneration or death of motor neurons in brain stem, spinal cord or motor cortex. These medicaments may be administered orally, intravenously, intraperitoneal, subcutaneous, intramuscular, intranasal or transdermal. | 2010-06-10 |
20100144892 | METHOD OF PRODUCING ORGANIC CERTIFIED GLYCERIN - A process for the production of naturally and organically fermented glycerin includes cleaning and sanitizing of the fermentation equipment prior to fermentation without using any traditional synthetic organic hydrocarbon-based chemicals. The fermentation process uses a non-chemical nutrient and nitrogen source from natural proteins during the fermentation to reduce trace amounts of toxins or contaminants. A purification stage following the fermentation process increases the purity of the glycerin to a desired level. | 2010-06-10 |
20100144893 | ISOPRENOID SYNTHASES - The invention relates to the field of genetic engineering of flavor, fragrance and biocontrol agent development. More specifically it relates to a process for production of natural flavors, fragrances or bio-control agents by the control of one or more genes implicated in that process. The invention provides an isolated or recombinant nucleic acid or functional fragment thereof encoding a proteinaceous molecule essentially capable of flavor, fragrance and/or bio-control agent synthesis when provided with a suitable substrate under appropriate reaction conditions. The invention further provides a nucleic acid or functional fragment thereof encoding a proteinaceous molecule essentially capable of synthesizing at least a monoterpene alcohol linalool when contacted with geranyl diphosphate (GPP) and/or at least a sesquiterpene alcohol nerolidol when contacted with farnesyl diphosphate (FPP) under appropriate reaction conditions. | 2010-06-10 |
20100144894 | USE OF DICALCIUM PHOSPHATE ANHYDRIDE POWDER - Dicalcium phosphate anhydride powder of which at least 50% by weight is of a grain size of between 45 and 150 μm, a maximum of 50% by weight is of a grain size of <45 μm and a maximum of 5% by weight is of a grain size >150 μm and which has a bulk density of between 1000 and 1500 g/l and a specific surface area of <5 m | 2010-06-10 |
20100144895 | EMBOLIC COMPOSITIONS WITH NON-CYANOACRYLATE RHEOLOGY MODIFYING AGENTS - Compositions for embolization are disclosed herein. The compositions disclosed can have a matrix-forming component, a solid-aggregate material, and a rheology modifying agent, wherein the matrix-forming component includes at least alkyl cyanoacrylate monomers, a stabilizer, and a plasticizer, and the solid-aggregate material includes at least a radiopacifier. The composition and a method of administering the composition are useful for treating vasculature abnormalities, particularly when the composition solidifies upon contact with an ionic environment, such as blood. | 2010-06-10 |
20100144896 | THIXOTROPIC PHARMACEUTICAL COMPOSITIONS - The present invention relates to a thixotropic pharmaceutical composition in which the viscosity is changed due to external mechanical stress applied so that isothermal and continuous gel/sol/gel transition occurs. The thixotropic pharmaceutical composition includes a pharmacologically active substance, a biocompatible thickener having a predetermined thixotropic property, and optionally a hydrophilic thickener. The viscosity of the composition is relatively rapidly changed within a predetermined range. Accordingly, it is easy to measure the amount of drugs to be administered, it is possible to administer a precise amount of drugs to a patient, the compliance of a patient with dosage of drugs is high, and it is easy to produce the composition. | 2010-06-10 |
20100144897 | Methicone replacements for cyclomethicone - The invention is directed to a dry feeling silicone that not only provides a dry feel when applied to skin, but also has a low surface tension, provides spreadability and contains essentially no cyclic silicones and additionally and importantly cannot is not form to make cyclomethicone. The ability to make a product that (1) has the dry feel, (2) is cyclomethicone free, (3) is not capable of making cyclomethicone when exposed to catalyst and (4) is not flammable is a long felt need, unsatisfied need in the cosmetic industry. | 2010-06-10 |
20100144898 | MIXTURE COMPRISING AN ALKYLPOLYGLUCOSIDE, A COSURFACTANT AND A POLYMER ADDITIVE - A mixture comprising a component I comprising 80-20% by weight of a first surfactant component I | 2010-06-10 |
20100144899 | METHOD FOR PREPARING NANO-EMULSIONS - The present invention relates to a method for preparing nano-emulsions comprising at least one aqueous continuous phase and at least one oily dispersed phase, comprising the steps of:
| 2010-06-10 |
20100144900 | Stereo Photo Hydrofel, a Process of Making Said Stereo Photo Hydrogel, Polymers for Use in Making Such Hydrogel and a Pharmaceutical Comprising Said Polymers - The Invention relates to a stereo photo hydrogel formed by stereo complexed and photo cross-linked polymers, which polymers comprise at least two types of polymers having at least one hydrophilic component, at least one hydrophobic mutually stereo complexing component, and at least one of the types comprises at least one photo cross-linkable component, to a process of making stereo photo hydrogel comprising the steps of a. providing a mixture of at least two types of polymers having at least one hydrophilic component, at least one hydrophobic mutually stereo complexing component and at least one of the types comprises at least one photo cross-linkable component; b. stereo complexing the two types of polymers, thereby forming a stereo complexed hydrogel; and c. photo cross-linking the stereo complexed hydrogel using visible or UV irradiation, thereby forming the stereo photo hydrogel, to such polymers for use in such hydrogel, and to a pharmaceutical kit comprising same. | 2010-06-10 |
20100144911 | DEPOLYMERIZATION OF POLYMERS - A method of depolymerizing formulated rubbers and polymer solids is described. The method utilizes a solvent at or above the solvent's critical pressure and critical temperature with a low ratio of solvent to the solid material. The resulting depolymerized material in either substantially solid or highly viscous liquid form can be repolymerized with the addition of more monomer. | 2010-06-10 |